Get the Stockscreener App
8.665
4.58%
0.335
Novavax Inc stock is traded at $8.665, with a volume of 2.78M.
It is up +4.58% in the last 24 hours and up +9.17% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$8.33
Open:
$8.43
24h Volume:
2.78M
Relative Volume:
0.46
Market Cap:
$1.41B
Revenue:
$1.08B
Net Income/Loss:
$422.82M
P/E Ratio:
3.8004
EPS:
2.28
Net Cash Flow:
$-637.33M
1W Performance:
-4.06%
1M Performance:
+9.17%
6M Performance:
+48.67%
1Y Performance:
-30.47%
1-Day Range:
$8.33
$8.7356
1-Week Range:
$8.24
$9.60
52-Week Range:
$5.01
$13.34
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.665 | 1.35B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.99 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
803.71 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.86 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Can Novavax Inc. stock sustain market leadershipJuly 2025 Reactions & Free Growth Oriented Trading Recommendations - newser.com
Intraday pattern recognizer results for Novavax Inc.Portfolio Risk Summary & Stock Market Timing Techniques - newser.com
How Novavax Inc. stock compares to market leaders2025 Institutional Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
Tools to assess Novavax Inc.’s risk profileRecession Risk & Fast Entry Momentum Trade Alerts - newser.com
What analysts say about Novavax Inc NVV1 stockSwing Trading Watchlist & High Profit Growth Stocks - earlytimes.in
Novavax starts late-stage trial of COVID-19 vaccine in United States - Reuters
Novavax Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Will Novavax Inc. continue its uptrendPortfolio Return Summary & Expert Approved Momentum Trade Ideas - newser.com
Statistical indicators supporting Novavax Inc.’s strengthJuly 2025 Analyst Calls & Real-Time Volume Spike Alerts - newser.com
Analyzing Novavax Inc. with risk reward ratio chartsTrade Ideas & Long-Term Investment Growth Plans - newser.com
Is Novavax Inc. stock attractive after correctionWeekly Volume Report & Weekly High Conviction Ideas - newser.com
Automated trading signals detected on Novavax Inc.2025 Volatility Report & Fast Entry High Yield Tips - newser.com
Is Novavax Inc. (NVV1) stock a buy on weakness2025 Pullback Review & Scalable Portfolio Growth Methods - newser.com
Is Novavax Inc. showing signs of accumulationMarket Performance Summary & Reliable Volume Spike Trade Alerts - newser.com
What institutional flow reveals about Novavax Inc.July 2025 Final Week & Fast Gain Stock Tips - newser.com
Novavax Inc Completes EU Marketing Authorization Transfer for Nuvaxovid - TradingView
Novavax Inc. Stock Slides 3.5%, Underperforms Peers - 富途牛牛
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - Yahoo Finance
Novavax, Inc. Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M - GuruFocus
Shah Capital Management Has $72.52 Million Stock Position in Novavax, Inc. $NVAX - MarketBeat
Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU - Seeking Alpha
Novavax Continues to Deliver on Sanofi Partnership, Completion Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment - MarketScreener
Novavax Completes Transfer of Marketing Authorization for COVID-19 Vaccine in EU to Sanofi - MarketScreener
Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax - GuruFocus
Novavax receives $25 million milestone payment from Sanofi partnership - Investing.com
Novavax Transfers EU Vaccine Rights to Sanofi - TipRanks
$25M Milestone: Novavax Transfers Nuvaxovid EU Authorization to Sanofi; Eligible for Up to $350M - Stock Titan
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Novavax Inc Stock Analysis and ForecastMerger & Acquisition Updates & Free Fastest Return On Investment - earlytimes.in
Is Novavax Inc. stock attractive for retirement portfoliosQuarterly Profit Review & Short-Term High Return Strategies - newser.com
Will Novavax Inc. (NVV1) stock benefit from sector leadershipJuly 2025 Short Interest & Weekly Top Performers Watchlists - newser.com
Smart tools for monitoring Novavax Inc.’s price actionMarket Growth Summary & Breakout Confirmation Alerts - newser.com
Will Novavax Inc. outperform the marketStop Loss & Verified Momentum Stock Watchlist - newser.com
Can Novavax Inc. rally from current levelsTrade Volume Report & AI Powered Buy/Sell Recommendations - newser.com
Using Bollinger Bands to evaluate Novavax Inc.Analyst Downgrade & High Yield Stock Recommendations - newser.com
Will Novavax Inc. stock benefit from AI adoptionQuarterly Growth Report & High Accuracy Investment Entry Signals - newser.com
Analyzing recovery setups for Novavax Inc. investorsWeekly Trade Summary & Weekly High Return Forecasts - newser.com
Novavax (NVAX) Is Up 10.6% After Sanofi Expands Matrix-M Licensing AgreementHas the Bull Case Changed? - Yahoo Finance
Novavax Inc. (NVAX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
A Fresh Look at Novavax (NVAX) Valuation After Recent Share Price Rebound - Yahoo Finance
Novavax allows Sanofi to use Matrix-M adjuvant for pandemic flu candidate - MSN
Novavax, Inc. (NASDAQ:NVAX) Held Back By Insufficient Growth Even After Shares Climb 27% - 富途牛牛
Noteworthy Wednesday Option Activity: ONON, NVAX, COMM - Nasdaq
Novavax’s Vaccine Milestone and Market Movement - StocksToTrade
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novavax Inc Stock (NVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Alton Gregg H | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
28,805 |
| King Rachel K. | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,190 |
| Rodgers Richard J | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
24,690 |
| MOTT DAVID M | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
60,890 |
| DOUGLAS RICHARD | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
54,340 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):